|
Biotecnologia Aplicada
Elfos Scientiae
ISSN: 0684-4551
Vol. 14, Num. 1, 1997, pp. 58
|
Biotecnologia Aplicada 1997 Volume 14 No. 1, pp.58
A DIFFERENT METHOD FOR OBTAINING AN ENGINEERED MURINE ANTIBODY, THAT
RECOGNIZES EPIDERMAL GROWTH FACTOR RECEPTOR, WITH REDUCED
IMMUNOGENICITY
Cristina Mateo, Josefa Lombardero, Ernesto Moreno, Gumersinda Bombino and
Rolando Perez
Center of Molecular Immunology, P.O. Box 16040. Havana, Cuba.
Code Number:BA970019
Size of Files:
Text: 5.6K
Graphics: No associated graphics files
Introduction
Monoclonal antibody producing hybridomas have been most readily obtained
from immunized rodents. In most cases where rodent antibodies have been
used for therapy, the recipients have elicited an immune response directed
towards the antibody. These reactions have limited the duration and
effectiveness of the therapy. The engineered antibodies have been designed
to replace as much as possible the xenogeneic sequences with the equivalent
human sequences. Chimeric and humanized antibodies are among the
genetically-engineered antibodies (1, 2). It is worth noting that even the
replacement of the constant regions with human equivalents may not abolish
their immunogenicity, still approximately half of the recipients mounts an
immune response to the rodent variable regions.
A further procedure for the humanization of an antibody has been suggested
by Padlan (3). It is based on the fact that the antigenicity of a protein
is dependent on the nature of its surface; therefore, a number of the
solvent-accesible residues in the rodent variable region are substituted by
residues from a human antibody.
Several groups have developed automated-computarized methods for the
identification of sequence features and structural determinants that play a
role in the MHC restriction of helper T-cell antigenic peptides (4, 5).
Using these algorithms, it has been possible to identify predicted T cell-
presented peptides.
Here we describe a new method to reduce immunogenicity through the
humanization of the predicted T cell epitopes present in the sequence of
the heavy chain variable region of an anti-epidermal growth factor receptor
murine monoclonal antibody.
Results and Discussion
The heavy chain variable region sequence of MAb R3 was analyzed for T cell
antigenic sequences by using the computer algorithm AMPHI (4), which
predicts segments of the sequences of eleven amino acids in length with an
amphipatic helix structure, which most likely could bind to MHC II
molecules.
Five amphipatic peptides were identified. Two of them involved CDR2 and
CDR3 and therefore were not considered for amino acid replacements.
Possible murine T cell epitopes in the framework regions were: H3-H13,
H8-H20, H74-H84.
The whole murine heavy chain variable region sequence was compared by
homology searching with the human sequences included in the Gene Bank and
EMBL databases. A human sequence was found having 75 % homology with the FR
regions. Two complementary strategies were followed to reduce
immunogenicity by replacing the murine amino acids in some positions,
according to the human sequence identified. Two amino acid replacements in
FR1: Leu11 by Val and Val12 by Lys, were enough to break the amphipatic
helix segments. Four amino acid replacements were required for the complete
humanization of the H74-H84 peptide: Ser75 by Thr, Thr76 by Ser, Ala78 by
Val, Thr83 by Arg. Computer modeling of the MAb R3 variable region
suggested that the proposed amino acid replacements should not have any
influence in binding affinity. Positions 11, 12 and 83 were distant from
CDRs/FRs interface. Ser75 residue was pointing to the outside; on the other
hand, Thr76 was accesible from the top of the molecule, but the
substitution by Ser was a conservative change. The replacement of Ala78 by
Val should not require steric rearrangements.
We had previously obtained a humanized version of the MAb R3 by CDR-
grafting (this volume). The FRs of the human immunoglobulin REI was
selected for VK region. NSO myeloma cells were cotransfected with pSV
expression vectors containing both the modified quimeric heavy chain and
the humanized light chain. The hybrid recombinant antibodies were tested
using radio receptor assay for their ability to compete with EGF binding to
its receptor, having the same affinity as the original murine antibody (8 x
10^-9 M).
Cercopithecus aethiops monkeys (two in each group) were immunized with
murine, humanized and mutant hybrid MAb R3. A high IgG response to murine
MAb R3 was obtained when this antibody was used as immunogen after two
immunizations. A lower but still measurable IgG response (1/10 000 sera
dilution) to the murine MAb R3 was obtained when monkeys were immunized
four times either with the humanized antibody or with the VH mutant
version.
Experiments are in progress with a complete VH and VK mutant version of the
quimeric recombinant MAb R3.
References
1. Morrison SL et al. Proc Natl Acad Sci USA 1984;81:6851-6855.
2. Reichmann L et al. Nature 1988; 322: 21-25.
3. Padlan EA. Molecular Immunology 1991;28:489-498.
4. Berzofsky JA et al. The Journal of Immunology 1987;138:2213-
2229.
5. Reyes VE et al. The Journal of Biological Chemistry
1989;264:12854-12858.
Copyright 1997 Elfos Scientiae
|